Immunization of Humans with Polyribophosphate, the Capsular Antigen of <i>Hemophilus influenzae</i>, Type b

Porter Anderson; Georges Peter; Richard B. Johnston; Leslie H. Wetterlow; David H. Smith

doi:10.1172/JCI106794

Immunization of Humans with Polyribophosphate, the Capsular Antigen of Hemophilus influenzae, Type b

Published January 1, 1972 - More info

View PDF

Abstract

In human volunteers, single injections of purified polyribophosphate elicited antibodies detectable by passive hemagglutination and by serum bactericidal and opsonizing activities against viable Hemophilus influenzae, type b. All three activities rose by 2 wk to maximal levels, at which they remained for at least 6 months. Doses of 1 μg elicited antibody responses in nearly all recipients; higher doses of the antigen, however, produced larger increases in titer. Booster doses of 1 μg given at 6 months did not further increase the antibody titers. A tuberculin-like response was often observed at the site of injections given intradermally.

Images.

Immunization of Humans with Polyribophosphate, the Capsular Antigen of Hemophilus influenzae, Type b

Porter Anderson, Georges Peter, Richard B. Johnston Jr., Leslie H. Wetterlow, and David H. Smith

Article tools

Metrics

Go to

Immunization of Humans with Polyribophosphate, the Capsular Antigen of Hemophilus influenzae, Type b

Porter Anderson, Georges Peter, Richard B. Johnston Jr., Leslie H. Wetterlow, and David H. Smith

Article tools

Metrics

Go to

Sign up for email alerts